Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Exalenz Bioscience
Modi’in, Central, Israelexalenz.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Exalenz’s flagship product, the BreathID platform, is a non-invasive urea breath test system for rapid detection of H. pylori infection and other GI/liver conditions. The system is FDA-cleared and CE-marked; it delivers results in 10–15 minutes with high sensitivity and specificity. It has been adopted in over 400 U.S. medical centers and major labs[1][3][6].
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- Device
- Industry
- Metabolite Diagnostics
02
Partnerships
No major external pharma/biotech partnerships reported; now integrated into Meridian’s diagnostics business.
Beyond the preview
Go deeper on Exalenz Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exalenz Bioscience.